Stromal cells and osteoclasts are responsible for exacerbated collagen-induced arthritis in interferon-beta-deficient mice.

OBJECTIVE Clinical trials using interferon-beta (IFNbeta) in the treatment of rheumatoid arthritis have shown conflicting results. We undertook this study to understand the mechanisms of IFNbeta in arthritis at a physiologic level. METHODS Collagen-induced arthritis (CIA) was induced in IFNbeta-deficient and control mice. The role of IFNbeta was investigated in both the priming and effector phases of the disease. The effect of IFNbeta deficiency on synovial cells, macrophages, and fibroblasts from preimmunized mice was analyzed by flow cytometry, immunohistochemistry, and enzyme-linked immunosorbent assay. Differences in osteoclast maturation were determined in situ by histology of arthritic and naive paws and by in vitro maturation studies of naive bone marrow cells. The importance of IFNbeta-producing fibroblasts was determined by transferring fibroblasts into mice at the time of CIA immunization. RESULTS Mice lacking IFNbeta had a prolonged disease with a higher incidence compared with control mice. IFNbeta deficiency was found to influence the effector phase, but not the priming phase, of arthritis. Compared with control mice, IFNbeta-deficient mice had greater infiltration of CD11b+ cells and greater production of tumor necrosis factor alpha in vivo, and their macrophages and fibroblasts were both more activated in vitro. Moreover, IFNbeta-deficient mice generated a greater number of osteoclasts in vitro, and mice immunized to induce arthritis, but not naive mice, had a greater number of osteoclasts in vivo compared with control mice. Importantly, IFNbeta-competent fibroblasts were able to ameliorate arthritis in IFNbeta-deficient recipients. CONCLUSION Our data indicate that IFNbeta is involved in regulating the activation state of osteoclasts and stromal cells, including macrophages and fibroblasts, but that it has little effect on T cells.

[1]  K. Rajewsky,et al.  From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. , 1999, Immunity.

[2]  M. Jensen,et al.  Interferon β decreases T cell activation and interferon γ production in multiple sclerosis , 1993, Journal of Neuroimmunology.

[3]  P. Tak,et al.  Interferon-β for treatment of rheumatoid arthritis? , 2002, Arthritis research.

[4]  P. Tak,et al.  The expression of IFN-β in synovial tissue from rheumatoid arthritis patients compared to osteoarthritis and reactive arthritis patients , 2002, Arthritis Research.

[5]  R. Holmdahl,et al.  Collagen-induced arthritis development requires αβ T cells but not γδ T cells: studies with T cell-deficient (TCR mutant) mice , 1999 .

[6]  Kutty Selva Nandakumar,et al.  Collagen type II-specific monoclonal antibody-induced arthritis in mice: description of the disease and the influence of age, sex, and genes. , 2003, The American journal of pathology.

[7]  P. Tak.  IFN-beta in rheumatoid arthritis. , 2004, Frontiers in bioscience : a journal and virtual library.

[8]  C. Polman,et al.  Recombinant interferon-ß blocks proliferation but enhances interleukin-10 secretion by activated human T cells , 2012 .

[9]  G. Firestein,et al.  How important are T cells in chronic rheumatoid synovitis? , 1990, Arthritis and rheumatism.

[10]  Hiroshi Takayanagi,et al.  T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ , 2000, Nature.

[11]  R. Holmdahl,et al.  Identification of an immunodominant type‐II collagen peptide recognized by T cells in H‐2q mice: self tolerance at the level of determinant selection , 1992, European journal of immunology.

[12]  J. Lord,et al.  Inhibition of Neutrophil Apoptosis by Type 1 IFN Depends on Cross-Talk Between Phosphoinositol 3-Kinase, Protein Kinase C-δ, and NF-κB Signaling Pathways1 , 2003, The Journal of Immunology.

[13]  C. Ritchlin,et al.  Fibroblast biology: Effector signals released by the synovial fibroblast in arthritis , 2000, Arthritis research.

[14]  T. Leanderson,et al.  Interferon-β is required for interferon-α production in mouse fibroblasts , 1998, Current Biology.

[15]  P. Tak,et al.  Treatment with recombinant interferon-β reduces inflammation and slows cartilage destruction in the collagen-induced arthritis model of rheumatoid arthritis , 2004, Arthritis research & therapy.

[16]  A. Verma,et al.  Critical roles for IFN-β in lymphoid development, myelopoiesis, and tumor development: Links to tumor necrosis factor α , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[17]  M. Dallman,et al.  Impaired Antiviral Response and Alpha/Beta Interferon Induction in Mice Lacking Beta Interferon , 2000, Journal of Virology.

[18]  C. Buckley,et al.  Michael Mason prize essay 2003. Why do leucocytes accumulate within chronically inflamed joints? , 2003, Rheumatology.

[19]  Kenneth W. Adolph,et al.  Human genome methods , 1998 .

[20]  G. Lutfalla,et al.  Genetic transfer of a functional human interferon α receptor into mouse cells: Cloning and expression of its c-DNA , 1990, Cell.

[21]  Manna Zhang,et al.  Different effects of rat interferon alpha, beta and gamma on rat hepatic stellate cell proliferation and activation , 2002, BMC Cell Biology.

[22]  K. Uetsuka,et al.  Immunohistochemical study on type II collagen-induced arthritis in DBA/1J mice. , 1997, Experimental animals.

[23]  Richard O. Williams,et al.  Amelioration of collagen-induced arthritis and suppression of interferon-?, interleukin-12, and tumor necrosis factor ? production by interferon-? gene therapy , 1999 .

[24]  D. Isenberg,et al.  Compromised Function of Regulatory T Cells in Rheumatoid Arthritis and Reversal by Anti-TNFα Therapy , 2004, The Journal of experimental medicine.

[25]  David H. Miller,et al.  Multiple Sclerosis and Its Treatment , 1999, Journal of the Royal College of Physicians of London.

[26]  M. Dallman,et al.  Immunisation against heterologous type II collagen induces arthritis in mice , 1980, Nature.

[27]  R. Zinkernagel,et al.  Immune Defence in Mice Lacking Type I and/or Type II Interferon Receptors , 1995, Immunological reviews.

[28]  P. Tak,et al.  Expression of interferon β in synovial tissue from patients with rheumatoid arthritis: comparison with patients with osteoarthritis and reactive arthritis , 2005, Annals of the rheumatic diseases.

[29]  F. Breedveld,et al.  The effects of interferon-β treatment on synovial inflammation and expression of metalloproteinases in patients with rheumatoid arthritis , 2000 .

[30]  L. Klareskog,et al.  High antibody response to autologous type II collagen is restricted to H-2q , 2004, Immunogenetics.

[31]  D. Fox,et al.  The role of T cells in the immunopathogenesis of rheumatoid arthritis: new perspectives. , 1997, Arthritis and rheumatism.

[32]  E. J. Miller.  Structural studies on cartilage collagen employing limited cleavage and solubilization with pepsin. , 1972, Biochemistry.

[33]  E. Vuorio,et al.  Systemic versus cartilage-specific expression of a type II collagen-specific T-cell epitope determines the level of tolerance and susceptibility to arthritis. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[34]  R. Holmdahl,et al.  IFN-β Gene Deletion Leads to Augmented and Chronic Demyelinating Experimental Autoimmune Encephalomyelitis1 , 2003, The Journal of Immunology.

[35]  F. Jungo,et al.  IFN-β INHIBITS THE ABILITY OF T LYMPHOCYTES TO INDUCE TNF-α AND IL-1β PRODUCTION IN MONOCYTES UPON DIRECT CELL–CELL CONTACT , 2001 .

[36]  R. Holmdahl,et al.  B cell‐deficient mice do not develop type II collagen‐induced arthritis (CIA) , 1998, Clinical and experimental immunology.

[37]  S. Issazadeh-Navikas,et al.  Upregulation of B7 molecules (CD80 and CD86) and exacerbated eosinophilic pulmonary inflammatory response in mice lacking the IFN-beta gene. , 2003, The Journal of allergy and clinical immunology.

[38]  F. Breedveld,et al.  The effects of interferon beta treatment on arthritis. , 1999, Rheumatology.

[39]  G. Herrero-Beaumont,et al.  A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis , 2004, Annals of the rheumatic diseases.

[40]  D. Isenberg,et al.  Anti-B cell therapy (rituximab) in the treatment of autoimmune diseases. , 2004, Lupus.

[41]  R. Holmdahl,et al.  The B cell response to autologous type II collagen: biased V gene repertoire with V gene sharing and epitope shift. , 1996, Journal of immunology.

[42]  T. Taniguchi,et al.  Signaling crosstalk between RANKL and interferons in osteoclast differentiation , 2002, Arthritis research.

[43]  B. Cohen,et al.  The human interferon α β receptor: Characterization and molecular cloning , 1994, Cell.

[44]  Kutty Selva Nandakumar,et al.  Collagen type II (CII)-specific antibodies induce arthritis in the absence of T or B cells but the arthritis progression is enhanced by CII-reactive T cells , 2004, Arthritis research & therapy.

[45]  M. Feldmann,et al.  Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. , 2000, Arthritis and rheumatism.

[46]  M. Biffoni,et al.  Incidence of antibodies to interferon-beta in patients treated with recombinant human interferon-beta 1a from mammalian cells. , 1997, Cytokines, cellular & molecular therapy.